NCI declares state of crisis in trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

An NCI report concluded that our clinical trial system is nearing a “state of crisis.” This seems like a case of new report, same conclusion.

An NCI report concluded that our clinical trial system is nearing a "state of crisis." This seems like a case of new report, same conclusion. "A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program," identified reasons for our system's lack of production including the time it takes to organize and launch a trial: More than two years of slugging through a Kafkaesque maze of bureaucracy and, if the trial finishes at all, the compound or therapy has a good chance of being out of date. Randomized controlled trials are still the gold standard for cancer agents to move from bench to bedside. We need to make it a national priority to streamline this overwrought process.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content